Summary & Overview
HCPCS A9561: Technetium tc-99m Oxidronate for Bone Imaging
HCPCS Level II code A9561 represents a diagnostic radiopharmaceutical: technetium tc-99m oxidronate, per study dose up to 30 millicuries, primarily used for bone scintigraphy. This code identifies the drug component of nuclear medicine bone imaging studies and matters nationally because radiopharmaceutical coding affects clinical workflows, billing accuracy, and payer coverage determinations across hospital outpatient departments, imaging centers, and nuclear medicine clinics. Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise review of the clinical context for use in bone imaging, the places of service where this product is typically administered, and the billing implications of using a radiopharmaceutical-specific HCPCS Level II code. The publication summarizes common modifiers and procedural relationships (Data not available in the input), clarifies where to locate related procedural and diagnostic codes, and outlines benchmarking and policy topics relevant to payers nationally. The report is intended to help revenue cycle, billing, and clinical staff recognize how HCPCS Level II code A9561 fits into diagnostic nuclear medicine service lines and payer claim adjudication processes.
Billing Code Overview
HCPCS Level II code A9561 describes Technetium tc-99m oxidronate, diagnostic, per study dose, up to 30 millicuries. This radiopharmaceutical is used for diagnostic nuclear medicine bone imaging studies to evaluate skeletal pathology.
Service type: Diagnostic nuclear medicine radiopharmaceutical administration
Typical site of service: Hospital outpatient imaging departments, independent nuclear medicine clinics, and ambulatory imaging centers
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult referred for a bone scintigraphy using technetium Tc-99m oxidronate A9561 to evaluate suspected skeletal pathology. Common presentations include focal bone pain after trauma, unexplained persistent localized skeletal pain, staging or surveillance of metastatic bone disease in known malignancy, evaluation of suspected osteomyelitis when radiographs are inconclusive, or assessment of complex regional pain syndrome. The clinical workflow begins with an order from the referring clinician (orthopedics, oncology, primary care, or infectious disease). The nuclear medicine department verifies indications, allergies, pregnancy status, and recent radiologic studies. The radiopharmacy dispenses Technetium Tc-99m oxidronate up to the study dose (up to 30 millicuries) and documents lot numbers and activity. The patient receives the radiotracer intravenously, a waiting period allows tracer uptake (commonly 2–4 hours for delayed whole-body/bone imaging), and planar and/or SPECT/SPECT-CT imaging is acquired. Interpreting physician documents findings, impression, and any limitations. Billing uses HCPCS Level II code A9561 for the radiopharmaceutical per study dose, and facility and professional components are billed as applicable. Patient preparation, consent for ionizing radiation, and radiation safety counseling are part of the workflow.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|